Abstract

Introduction/BackgroundARTISTRY-7 will evaluate the novel engineered cytokine nemvaleukin alfa (nemvaleukin) in gynaecologic cancers. Nemvaleukin was designed to selectively bind to the intermediate-affinity interleukin-2 (IL-2) receptor, preferentially activating antitumour CD8+ T...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326)
Thomas Herzog ... Julie Graham
Gynecologic oncology | VOL. 166
Thomas Herzog, et. al.Thomas Herzog ... Julie Graham
01 Aug 2022
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Thomas J Herzog ... Julie R Graham
Journal of Clinical Oncology | VOL. 40
Thomas J Herzog, et. al.Thomas J Herzog ... Julie R Graham
01 Jun 2022
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
Thomas J Herzog ...
Journal of Clinical Oncology | VOL. 41
Thomas J Herzog, et. al.Thomas J Herzog ...
01 Jun 2023
2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)
Thomas J Herzog ... Rita Dalal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 32
Thomas J Herzog, et. al.Thomas J Herzog ... Rita Dalal
01 Oct 2022
View more papers

More From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Paper Title
Journal
Date
Author
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA
Giorgia Dinoi ... Francesco Fanfani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Giorgia Dinoi, et. al.Giorgia Dinoi ... Francesco Fanfani
13 Jul 2024
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
Violante Di Donato ... Giorgio Bogani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Violante Di Donato, et. al.Violante Di Donato ... Giorgio Bogani
13 Jul 2024
Higher incidence of venous thromboembolism associated with increasing lines of treatment in heavily treated ovarian cancer patients
Erika J Lampert ... Mariam M Alhilli
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Erika J Lampert, et. al.Erika J Lampert ... Mariam M Alhilli
13 Jul 2024
Antibody–drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
Antonio Gonzalez-Martin
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Antonio Gonzalez-MartinAntonio Gonzalez-Martin
10 Jul 2024
View more papers